AusperBio raises $120m to progress hepatitis B therapies
AusperBio’s total capital raised since 2024 has reached $360m.
Drug Development
FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
FDA grants RPDD to ReviR’s RTX-117 for CMT
ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
McKesson to acquire Precision Medicine Group for $2.25bn
Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
